REDHILL BIOPHARMA LTD. Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019
REDHILL BIOPHARMA LTD. (RDHL) had Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 of $6310.15 per share as of 2024-12-31, per its 20-F filed 2025-04-10.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019 · last filed 2025-04-10
- 2024-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $6310.15.
- 2023-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $6228.50; Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 as first filed $249.14.
- 2022-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $249.20; Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 as first filed $6.23.
- 2021-12-31: Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 $6.14.
| Period end | Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 | Weighted Average Exercise Price Of Share Options Exercisable In Share-based Payment Arrangement2019 as first filed |
|---|---|---|
| 2024-12-31 | $6310.15 20-F · filed 2025-04-10 | |
| 2023-12-31 | $6228.50 20-F · filed 2025-04-10 | $249.14 20-F · filed 2024-04-08 |
| 2022-12-31 | $249.20 20-F · filed 2024-04-08 | $6.23 20-F · filed 2023-04-28 |
| 2021-12-31 | $6.14 20-F · filed 2023-04-28 | |
| 2020-12-31 | $10.19 20-F · filed 2022-03-17 | |
| 2019-12-31 | $11.40 20-F · filed 2021-03-18 | $1.14 20-F · filed 2020-03-04 |
| 2018-12-31 | $1.25 20-F · filed 2020-03-04 |